Literature DB >> 22278223

Distinct transformation tropism exhibited by human T lymphotropic virus type 1 (HTLV-1) and HTLV-2 is the result of postinfection T cell clonal expansion.

Priya Kannian1, Han Yin, Rami Doueiri, Michael D Lairmore, Soledad Fernandez, Patrick L Green.   

Abstract

Human T lymphotropic virus type 1 (HTLV-1) and HTLV-2 are related but pathogenically distinct viruses. HTLV-1 mainly causes adult T cell leukemia, while HTLV-2 is not associated with leukemia. In vitro, HTLV-1 and HTLV-2 predominantly transform CD4(+) and CD8(+) T cells, respectively: the genetic determinant maps to the viral envelope. Herein, we investigate whether this transformation tropism occurs during initial infection or subsequently during the cellular transformation process. Since most individuals are chronically infected at the time of detection, we utilized an established rabbit model to longitudinally measure the early HTLV-1 and HTLV-2 infection and replication kinetics in purified CD4(+) and CD8(+) T cells. HTLV-1 and HTLV-2 were detected in both CD4(+) and CD8(+) T cells within 1 week postinoculation. In HTLV-1-infected rabbit CD4(+) T cells, proviral burden and tax/rex mRNA expression peaked early, and expression levels were directly proportional to each other. The late expression of the antisense transcript (Hbz or Aph-2) correlated directly with a late proviral burden peak in HTLV-1- or HTLV-2-infected rabbit CD8(+) T cells, respectively. This study provides the first in vivo evidence that these viruses do not exhibit cellular preference during initial infection. We further evaluated the transformation tropism of HTLV-1 and HTLV-2 over a 9-week period using in vitro cell growth/immortalization assays. At the early weeks, both HTLV-1 and HTLV-2 showed proportionate growth of CD4(+) and CD8(+) T cells. However, beyond week 5, the predominance of one particular T cell type emerged, supporting the conclusion that transformation tropism is a postinfection event due to selective clonal expansion over time.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22278223      PMCID: PMC3302488          DOI: 10.1128/JVI.06900-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV.

Authors:  Nicolas Manel; Felix J Kim; Sandrina Kinet; Naomi Taylor; Marc Sitbon; Jean-Luc Battini
Journal:  Cell       Date:  2003-11-14       Impact factor: 41.582

2.  Regulation of the cell-surface expression of an HTLV-I binding protein in human T cells during immune activation.

Authors:  Manisha D Nath; Francis W Ruscetti; Cari Petrow-Sadowski; Kathryn S Jones
Journal:  Blood       Date:  2002-12-27       Impact factor: 22.113

3.  Functional role of pX open reading frame II of human T-lymphotropic virus type 1 in maintenance of viral loads in vivo.

Authors:  J T Bartoe; B Albrecht; N D Collins; M D Robek; L Ratner; P L Green; M D Lairmore
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  Fratricide among CD8(+) T lymphocytes naturally infected with human T cell lymphotropic virus type I.

Authors:  E Hanon; J C Stinchcombe; M Saito; B E Asquith; G P Taylor; Y Tanaka; J N Weber; G M Griffiths; C R Bangham
Journal:  Immunity       Date:  2000-11       Impact factor: 31.745

5.  Prevalence and clinical features of HTLV neurologic disease in the HTLV Outcomes Study.

Authors:  J R Orland; J Engstrom; J Fridey; R A Sacher; J W Smith; C Nass; G Garratty; B Newman; D Smith; B Wang; K Loughlin; E L Murphy
Journal:  Neurology       Date:  2003-12-09       Impact factor: 9.910

6.  Human T cell lymphotropic virus type I (HTLV-I)-specific CD4+ T cells: immunodominance hierarchy and preferential infection with HTLV-I.

Authors:  Peter K C Goon; Tadahiko Igakura; Emmanuel Hanon; Angelina J Mosley; Anna Barfield; Amanda L Barnard; Lambrini Kaftantzi; Yuetsu Tanaka; Graham P Taylor; Jonathan N Weber; Charles R M Bangham
Journal:  J Immunol       Date:  2004-02-01       Impact factor: 5.422

7.  Human T-cell leukemia virus type 1 envelope glycoprotein gp46 interacts with cell surface heparan sulfate proteoglycans.

Authors:  Josefina D Piñon; P J Klasse; Sushma R Jassal; Sandy Welson; Jonathan Weber; David W Brighty; Quentin J Sattentau
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

8.  Tax and overlapping rex sequences do not confer the distinct transformation tropisms of human T-cell leukemia virus types 1 and 2.

Authors:  Jianxin Ye; Li Xie; Patrick L Green
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

9.  HTLV-1 Rex is required for viral spread and persistence in vivo but is dispensable for cellular immortalization in vitro.

Authors:  Jianxin Ye; Lee Silverman; Michael D Lairmore; Patrick L Green
Journal:  Blood       Date:  2003-08-07       Impact factor: 22.113

10.  NF-κB hyper-activation by HTLV-1 tax induces cellular senescence, but can be alleviated by the viral anti-sense protein HBZ.

Authors:  Huijun Zhi; Liangpeng Yang; Yu-Liang Kuo; Yik-Khuan Ho; Hsiu-Ming Shih; Chou-Zen Giam
Journal:  PLoS Pathog       Date:  2011-04-28       Impact factor: 6.823

View more
  29 in total

1.  HBZ-mediated shift of JunD from growth suppressor to tumor promoter in leukemic cells by inhibition of ribosomal protein S25 expression.

Authors:  M Terol; H Gazon; I Lemasson; M Duc-Dodon; B Barbeau; R Césaire; J-M Mesnard; J-M Péloponèse
Journal:  Leukemia       Date:  2017-03-06       Impact factor: 11.528

2.  TCF1 and LEF1 act as T-cell intrinsic HTLV-1 antagonists by targeting Tax.

Authors:  Guangyong Ma; Jun-ichirou Yasunaga; Hirofumi Akari; Masao Matsuoka
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

3.  Role of Wild-type and Recombinant Human T-cell Leukemia Viruses in Lymphoproliferative Disease in Humanized NSG Mice.

Authors:  Devra D Huey; Brad Bolon; Krista M D La Perle; Priya Kannian; Steven Jacobson; Lee Ratner; Patrick L Green; Stefan Niewiesk
Journal:  Comp Med       Date:  2018-02-01       Impact factor: 0.982

4.  TAX and HBZ: hFc Ɣ 1 proteins as targets for passive immunotherapy.

Authors:  Mohammad Mehdi Akbarin; Houshang Rafatpanah; Saman Soleimanpour; Abbas Ali Amini; Amirali Arian; Arman Mosavat; Seyed Abdolrahim Rezaee
Journal:  Iran J Basic Med Sci       Date:  2022-05       Impact factor: 2.532

5.  Human T-cell leukemia virus type 3 (HTLV-3) and HTLV-4 antisense-transcript-encoded proteins interact and transactivate Jun family-dependent transcription via their atypical bZIP motif.

Authors:  Émilie Larocque; Charlotte André-Arpin; Malgorzata Borowiak; Guy Lemay; William M Switzer; Madeleine Duc Dodon; Jean-Michel Mesnard; Benoit Barbeau
Journal:  J Virol       Date:  2014-05-28       Impact factor: 5.103

6.  Is there a role for ubiquitin or SUMO in human T-cell leukemia virus type 2 Tax-induced NF-κB activation?

Authors:  Alfonso Lavorgna; Edward W Harhaj
Journal:  Future Virol       Date:  2013-03       Impact factor: 1.831

7.  Functional Comparison of HBZ and the Related APH-2 Protein Provides Insight into Human T-Cell Leukemia Virus Type 1 Pathogenesis.

Authors:  Amanda R Panfil; Nathan J Dissinger; Cory M Howard; Brandon M Murphy; Kristina Landes; Soledad A Fernandez; Patrick L Green
Journal:  J Virol       Date:  2016-01-27       Impact factor: 5.103

8.  Human T lymphotropic virus type 1 SU residue 195 plays a role in determining the preferential CD4+ T cell immortalization/transformation tropism.

Authors:  Priya Kannian; Soledad Fernandez; Kathryn S Jones; Patrick L Green
Journal:  J Virol       Date:  2013-06-19       Impact factor: 5.103

9.  Conference highlights of the 15th International Conference on Human Retrovirology: HTLV and related retroviruses, 4-8 June 2011, Leuven, Gembloux, Belgium.

Authors:  Fabiola Martin; Charles R M Bangham; Vincenzo Ciminale; Michael D Lairmore; Edward L Murphy; William M Switzer; Renaud Mahieux
Journal:  Retrovirology       Date:  2011-10-28       Impact factor: 4.602

Review 10.  The importance of ubiquitination and sumoylation on the transforming activity of HTLV Tax-1 and Tax-2.

Authors:  Linda Zane; Kuan-Teh Jeang
Journal:  Retrovirology       Date:  2012-12-07       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.